Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis

NCT ID: NCT01577628

Last Updated: 2016-04-21

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-06-30
• Study Completion Date: 2013-02-28

Brief Summary

There is a lack of prospective scientific data on the regular use of moisturizers in patients at risk of developing atopic dermatitis. Although generally accepted and widely used for secondary prevention, emollients have not been studied as a primary prevention strategy. Strategies previously studied for the prevention of atopic dermatitis include maternal and child's dietary manipulations, allergens avoidance, delay of food introduction, exclusive breastfeeding and probiotic supplementation. Despite years of research, none of those strategies yielded to strong evidence of a protective effect. There is therefore a need to explore novel strategies.

There is a need to compare the cumulative incidence rate of atopic dermatitis in newborns using a standard bathing and moisturizing routine with a good moisturizer to a non interventional group.

This 2-year study will recruit approximately four hundred and sixty (460) pregnant women with a first degree relative of the child to be born who currently has (or previously had) a diagnosis of atopic dermatitis in order to study approximately 200 eligible newborns in each of the two study groups at the beginning of the study.

Pregnant women will be randomized (1:1) to either daily use of the moisturizer Lipikar Balm AP (applied to their infant) starting from birth (Group 1) immediately after bathing or to no intervention (Group 2).

Detailed Description

To be eligible, pregnant women must be at least 16 weeks pregnant. Expecting mothers (or the father of the infant to be born) or related sibling of the child to be born must meet or previously have met criteria for atopic dermatitis. In addition, one of the parents or sibling of the child to be born must suffer from allergic rhinitis or asthma.

Pregnant women will be randomized at screening and their infant will be seen at 1 month, 6 months, 12 months (1 year) and 24 months (2 years) after birth.

Women randomized to group 1 will be requested to use the same body cleanser (Lipikar Syndet) and to apply Lipikar Balm AP to their child once daily immediately after bathing on a well blotted skin (within 3 minutes of bathing) to the entire body (including the face) from birth, while women randomized to group 2 will be in a non-interventional control group.

The presence of atopic dermatitis (using Hanifin's criteria(1)) and study products use will be assessed at 1 month, 6 months, 12 months and 24 months after birth. A buccal smear will be sampled from all infants at 1 month after birth for the genotyping of filaggrin (FLG) gene.

In addition, adverse events evaluation and parent questioning on infants development of food allergies and asthma will be performed at 1 month, 3 months (telephone visit), 6 months, 12 months and 24 months after birth. Infants will be followed for a total of two years after birth.

Lipikar Balm AP is a commonly used cosmetic moisturizer commercially available in many countries including Canada. This moisturizer is recommended for extreme dryness and atopy-prone skin in babies, children and adults. It contains shea butter, paraffin, waxes and vegetable oils. The high content in shea butter and the fraction chosen showed a greater expression of constitutive ceramids forming the barrier function of the skin (data on file at La Roche-Posay).

Conditions

Atopic Dermatitis; Eczema; Asthma; Food Allergies; Allergic Rhinitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Group 1: Lipikar Balm AP

Daily application of Lipikar Balm AP starting at birth

Group Type: OTHER

Lipikar Balm AP

Intervention Type: DRUG

Daily application of Lipikar Balm AP starting at birth

Group 2: No intervention control group

Subjects may use a moisturizer if they wish to but no instruction or product is provided

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Lipikar Balm AP

Daily application of Lipikar Balm AP starting at birth

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Women 18 years of age or older at the time of consent
• At least 16 weeks pregnant
• Women with a high risk of having a child with atopic dermatitis defined as having one parent or related sibling of the child to be born who currently (or previously) suffers from atopic dermatitis and who also suffers from asthma or allergic rhinitis
• Be willing to use the body cleanser Lipikar Syndet and to apply Lipikar Balm AP (if randomized to group 1) every day from birth for 2 years
• Capable of giving informed consent and the consent must be obtained prior to any study related procedures

Exclusion Criteria

• Preterm birth defined as birth before 37 weeks of gestation
• Major congenital anomaly at birth
• Presence of significant dermatitis at birth
• Any medical problem at birth that would prevent the daily use of Lipikar Syndet and/or Lipikar Balm AP (regardless of the group the subject was randomized to) or would prevent evaluation of the skin for the presence of atopic dermatitis

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Innovaderm Research Inc.

OTHER

Sponsor Role: collaborator

Cosmetique Active International

INDUSTRY

Sponsor Role: lead

Responsible Party

Robert BISSONNETTE

President and Dematologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Robert Bissonnette, MD, FRCPC

Role: PRINCIPAL_INVESTIGATOR

Innovaderm Research

Locations

Hamzavi Dermatology/Dermatology Specialists of Canton

Canton, Michigan, United States

Hamzavi Dermatology

Fort Gratiot, Michigan, United States

Lynderm Research

Markham, Ontario, Canada

Windsor Clinical Research

Windsor, Ontario, Canada

Countries

United States; Canada

Other Identifiers

LRP11005

Identifier Type: -

Identifier Source: org_study_id